SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACMI - Accumed Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sigmund who wrote (871)1/3/1998 3:57:00 AM
From: Cisco  Read Replies (1) of 1894
 
Sigmund:

Vector Securities doesn't address this directly, however let me share with you some of the things I will be looking for in 1998.

1. Filing during the 1st Quarter of an amendment to AccuMed's 510(k) approval of TracCell 2000 to include screening of monolayer slides with approval coming in late 2nd quarter or 3rd quarter.

2. Filing during the 1st Quarter of an amendment to AccuMed's 510(k) for approval of the TracCell 2500 with approval coming in 3rd quarter.

3. Filing during the 1st Quarter of an application for a 510(k) notification for the AccZone with approval in 2nd or 3rd quarter 1998.

4. Watch for a possible FDA filing in late 1998 on the AcCell Savant.

5. Look for AccuMed to satisfy NASDAQ on its Net Equity by end of 1st quarter.

6. Look for Total Operating Expense which has averaged $5.5 million during the first 3 quarters of 1997 to drop below $4.0 million in the 1st quarter of 1998 and stay there.

7. Look for the gross margin which is largely volume sensitive to start climbing from its current level of 32.2% by 2nd Quarter of 1998.
This number must be significantly higher by the end of the year if shareholders are to be happy.

8. Look for sale revenues to climb to at least $9.0 million/quarter by 3rd Quarter 1998.

9. Watch for consolidations and strategic alliances within the industry over the next 18 months.

10. EPS worse than the following will worry me: 4Q97 (0.12), 1Q98 (0.08), 2Q98 (0.04), 3Q98 (0.02), 4Q98 0.02.

11. Expect the majority of sales income to continue to come from the microbiology division in 1998. However, the hope that this company will become a dominate player rest within the cytopathology division.
Look for the cytopathology division to become the major source of income sometime in 1999.

This is a brief list of some of the things I will be looking for in 1998. What is on your list?

Cisco
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News